Medscape Medical NewsAll articles

OptimMRI

RebrAIn, SAS • Radiology • 07/21/2023

510(k)IEC 62304 Class B
FDA Summary PDF

Device Purpose

OptimMRI is a medical image processing software designed to aid neurosurgeons by processing pre-operative MR images to create 3D annotated models of the brain for functional neurosurgical planning. It employs semi-automatic segmentation and machine learning to localize key structures like the Subthalamic Nuclei (STN) and Ventral Intermediate Nucleus (VIM), demonstrating high accuracy in performance studies for these targets.

Summary

OptimMRI is a software application designed to assist qualified medical professionals in the processing, visualization, and interpretation of anatomical structures from medical images. Its primary function is to process pre-operative DICOM compatible MR images of the brain, generating 3D annotated models that aid users in neurosurgical functional planning by allowing them to display, review, analyze, annotate, interpret, and export data. Specifically, OptimMRI is indicated for use with other clinical methods to help localize critical brain regions such as the Subthalamic Nuclei (STN) and the Ventral Intermediate Nucleus (VIM). The software employs semi-automatic segmentation and machine learning models to create specialized annotations, marking regions of interest with 3D crosses. Performance studies, which involved 44 cerebral MRIs for STN analysis and 31 for VIM analysis, demonstrated high accuracy, with at least 90% of surface distances for STN or VIM being within 2.0mm when compared to reference devices. OptimMRI's STN localization performance is reported as identical to its predicate device, SIS Software, despite OptimMRI's limitation to pre-operative use, reliance on semi-automatic processes, and lack of fusion imaging. A distinguishing feature is OptimMRI's capability to localize the VIM, a function not available in its predicate device.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

OptimMRINeurosurgical PlanningMedical Image Processing3D Brain ModelingSubthalamic Nuclei (STN)Ventral Intermediate Nucleus (VIM)DICOMMR ImagesSemi-automatic SegmentationMachine Learning

Device Metadata

Submission Number
K230150
Company
RebrAIn, SAS
Panel
Radiology
Product Code
N/A
Data Type
Images
Clinical Function
Intervention
AI Function
Analysis
AI Subclass
quantification/feature localization

Relevant Clinical Questions

  • Q1. How does the performance of OptimMRI's semi-automatic segmentation for STN and VIM localization compare to fully manual segmentation by expert neuroradiologists in terms of accuracy and time efficiency?; What specific machine learning models are employed for the annotation of anatomic structures, and what was the training dataset size and diversity for these models?; Given that OptimMRI annotates regions of interest with 3D crosses rather than 3D segmented volumes, what is the clinical impact of this methodological difference on surgical planning precision for procedures targeting STN and VIM?; How does the lack of fusion imaging capability in OptimMRI affect its utility in complex neurosurgical cases where multi-modal image integration is typically beneficial?; What are the specific output formats beyond DICOM, and how seamlessly does OptimMRI integrate with various existing neurosurgical planning systems commonly used in clinical practice?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score5/100
SBOM Evidence⚠ Not mentioned in summary
Cyber Risk Assessment⚠ Not mentioned in summary
Postmarket Plan⚠ Not mentioned in summary
§524B ApplicableNo

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials
- Not detected
ML-BOMMachine Learning Bill of Materials(training data, machine learning, dataset, annotation)
✓ Detected
SaaSBOMSoftware-as-a-Service Bill of Materials
- Not detected
HBOMHardware Bill of Materials
- Not detected
CBOMCryptography Bill of Materials
- Not detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials
- Not detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of ML-BOM detected in AI-generated device summary.

• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.

• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.

• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
OptimMRI - RebrAIn, SAS | ESL FDA AI Device Intelligence